

29. Giardini A, Martin MT, Cahir C, et al. Toward appropriate criteria in medication adherence assessment in older persons: Position Paper. *Aging Clin Exp Res*. 2016;28(3):371-381.
30. Dima AL, Dedi D. Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data. *PLoS One*. 2017;12(4).
31. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. *Circulation*. 2009;119(23):3028-3035.
32. Kronish IM, Thorpe CT, Voils CI. Measuring the multiple domains of medication nonadherence: Findings from a Delphi survey of adherence experts. *Transl Behav Med*. 2021;11(1):104-113.
33. Ilardo ML, Speciale A. The community pharmacist: Perceived barriers and patient-centered care communication. *Int J Environ Res Public Health*. 2020;17(2).
34. Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. *Integr Pharm Res Pract*. 2017;6:37-46.
35. McLean G, Band R, Saunderson K, et al. Digital interventions to promote self-management in adults with hypertension systematic review and meta-analysis. *J Hypertens*. 2016;34(4):600-612.
36. Meddings J, Kerr EA, Heisler M, et al. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: Still no better than a coin toss. *BMC Health Serv Res*. 2012;12(1).
37. Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. *Arch Intern Med*. 2000;160(4):481-490.
38. Dietrich F, Zeller A, Haag M, et al. Communicating electronic adherence data to physicians – consensus-based development of a compact reporting form. *Int J Environ Res Public Health*. 2021;18(19).
39. Lerner BH. From careless consumptives to recalcitrant patients: the historical construction of noncompliance. *Soc Sci Med*. 1997;45(9):1423-1431.
40. Rafi F, Fatemi NS, Danielson E, et al. Compliance to treatment in patients with chronic illness: A concept exploration. *Iran J Nurs Midwifery Res*. 2014;19(2):159-167.
41. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol*. 2012;73(5):691-705.
42. Sabaté E. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
43. De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guideline (EMERGE). *Ann Intern Med*. 2018;169(1):30-35.
44. Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. *Ther Clin Risk Manag*. 2005;1(3):189-199.
45. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*. 2011;86(4):304-314.
46. Arnet I, Haefeli WE. Compliance: Fakten Perspektiven. *Managed Care*. 1998;3:27-31.
47. Penna R, Knowlton C. The need for pharmaceutical care. In: *Pharmaceutical Care*. Taylor & Francis; 1998:225-226.
48. Fallsberg M. Reflection on Medicines and Medication – a Qualitative Analysis among People on Long-Term Drug Regimens. Linköping University; 1991.
49. Rimer B, & GB. How Do Persuasive Health Messages Work? A Health Education Field Study. *Health Educ Q*. 1984;11(3):313-321.
50. Hatoum HT, HRA, & LBL. OBRA 90: Patient counseling-enhancing patient outcomes. *US pharmacist*. 1993;18(1):75-86.
51. Boeni F, Hersberger KE, Arnet I. Multidrug punch cards in primary care: A mixed methods study on patients' preferences and impact on adherence. *Front Pharmacol*. 2014;5(SEP).
52. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting. *JAMA*. 2003;289(9):1107-1116.
53. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: Three decades of research. A comprehensive review. *J Clin Pharm Ther*. 2001;26(5):331-342.
54. Col N FJKP. The Role of Medication Noncompliance and Adverse Drug Reactions in Hospitalizations of the Elderly. *Arch Intern Med*. 1990;150(4):841-845.
55. Bae SG, Kam S, Park KS, et al. Factors related to intentional and unintentional medication nonadherence in elderly patients with hypertension in rural community. *Patient Prefer Adherence*. 2016;10:1979-1989.
56. Dalli LL, Kilkenny MF, Arnet I, et al. Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS. *Br J Clin Pharmacol*. 2022;88(10):4427-4442.
57. Wawruch M, Wimmer G, Murin J, et al. Non-adherence to statin treatment in older patients with peripheral arterial disease depending on persistence status. *Biomedicines*. 2020;8(10):1-12.
58. Wawruch M, Petrova M, Tesar T, et al. Factors associated with non-adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in older patients with peripheral arterial disease. *Front Pharmacol*. 2023;14.
59. Kozma C, Dickson, Phillips, Meletiche. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. *Patient Prefer Adherence*. [Internet] 2013;509 [cited 2023 Dec 10].
60. Bruthans J, Berger J, Šoltés J, et al. Using the national electronic prescription system to determine the primary non-adherence to medication in the Czech Republic. *Front Pharmacol*. 2023;14.
61. Bauer AM, Schillinger D, Parker MM, et al. Health literacy and antidepressant medication adherence among adults with diabetes: The diabetes study of Northern California (DISTANCE). *J Gen Intern Med*. 2013;28(9):1181-1187.
62. Fernández A, Quan J, Moffet H, et al. Adherence to newly prescribed diabetes medications among insured Latino and white patients with diabetes. *JAMA Intern Med*. 2017;177(3):371-379.
63. Williams JLS, Walker RJ, Smalls BL, et al. Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. *Diabetes Management*. 2014;4(1):29-48.
64. Arnet I, Sahn LJ, Gregório J, et al. Development and validation of the 15-STARs – A novel self-report pharmacy-based questionnaire to screen for medication non-adherence. *Res Social Adm Pharm*. 2023;S1551-7411(23)00487-4.
65. Mokkink LB, Prinsen C, Patrick D, et al. COSMIN methodology for systematic reviews of Patient-Reported Outcome Measures (PROMs) – user manual. [Internet] 2018. [cited 2023 Dec 10] Available at: https://cosmin.nl/wp-content/uploads/COSMIN-syst-review-for-PROMs-manual_version-1_feb-2018.pdf.
66. Arnet I, Caloz S, Eickhoff C, et al. Psychometric Quality of Questionnaires on Medication Adherence – a Secondary Analysis. Live paper presentation at the 27th Annual Conference of ESPACOMP. Budapest, 2. 12. 2023.
67. Gregoriano C, Dieterle T, Breitenstein AL, et al. Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. *Respir Res*. 2019;20(1).
68. Torres-Robles A, Wiecek E, Tonin FS, et al. Comparison of interventions to improve long-term medication adherence across different clinical conditions: A systematic review with network meta-analysis. *Front Pharmacol*. 2018;9.
69. Mills EJ, Lester R, Thorlund K, et al. Interventions to promote adherence to antiretroviral therapy in Africa: A network meta-analysis. *Lancet HIV*. 2014;1(3):104-111.
70. Van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-lowering medication. *Cochrane Database of Systematic Reviews*. 2016;2016(12).
71. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Arch Intern Med*. 2006;166(17):1836-1841.
72. Dietrich FM, Hersberger KE, Arnet I. Benefits of medication charts provided at transitions of care: A narrative systematic review. *BMJ Open*. 2020;10(10).
73. Marquis J, Schneider MP, Payot V, et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. *Int J Clin Pharm*. 2013;35(6):1130-1136.
74. Berkhout C, Berbra O, Favre J, et al. Defining and evaluating the Hawthorne effect in primary care, a systematic review and meta-analysis. *Front Med (Lausanne)*. 2022;9.
75. Haskard Zolnerek KB, Dimatteo MR. Physician communication and patient adherence to treatment: A meta-analysis. *Med Care*. 2009;47(8):826-834.
76. Hepler CD, SLM. Opportunities and responsibilities in pharmaceutical care. *Am J Pharm Ed*. 1990;53:75-155.
77. Boeni F, Arnet I, Hersberger KE. Adherence counseling during patient contacts in Swiss community pharmacies. *Patient Prefer Adherence*. 2015;9:597-605.
78. Cipolle RJ, SLM and MPC. *Pharmaceutical Care Practice*. Health Professions Division; 1998.